Skip to Content
Merck
  • Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis.

Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis.

Analytical and bioanalytical chemistry (2014-05-13)
Weidong Dai, Peiyuan Yin, Ping Chen, Hongwei Kong, Ping Luo, Zhiliang Xu, Xin Lu, Guowang Xu
ABSTRACT

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Discovery of novel biomarkers for early HCC from other liver diseases such as cirrhosis is of great clinical benefit. In this study, a novel steroid hormone metabolomic method based on liquid chromatography-mass spectrometry combined with logistic regression analysis was applied to study the steroid hormone disorders and to screen potential urinary steroid hormone biomarkers of early HCC. Thirty-six urinary steroid hormones were detected and quantified in healthy controls, cirrhotic patients, and early HCC patients. Heat map analysis and multivariate statistical analysis suggested severe disorders of steroid hormone network and holistically decreased urinary steroid hormone pattern in cirrhotic and early HCC patients. Logistic regression analysis reveals that a panel of two urinary steroid hormones (epitestosterone and allotetrahydrocortisol) displayed excellent diagnostic capability for distinguishing early HCC from cirrhosis with area under the curve (AUC) = 0.938 of receiver operating characteristic (ROC) analysis. These results help to overcome the disadvantage of lower sensitivity and specificity of alpha-fetoprotein for distinguishing early HCC from cirrhosis. Our work shows that steroid hormone metabolomics is a promising biomarker tool for biomarker study of early HCC.

MATERIALS
Product Number
Brand
Product Description

Supelco
L-Ascorbic acid, analytical standard
Sigma-Aldrich
Methanol, NMR reference standard
Supelco
Methanol, analytical standard
Sigma-Aldrich
Methanol, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
L-Ascorbic acid, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-Ascorbic acid, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L-Ascorbic acid, meets USP testing specifications
Sigma-Aldrich
L-Ascorbic acid, reagent grade
Sigma-Aldrich
4-(Dimethylamino)benzaldehyde, suitable for histochemical demonstration of nitro blue tetrazolium reduction in neutrophils
Sigma-Aldrich
L-Ascorbic acid, reagent grade, crystalline
Sigma-Aldrich
L-Ascorbic acid, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L-Ascorbic acid, 99%
Sigma-Aldrich
4-(Dimethylamino)benzaldehyde, ACS reagent, 99%
Sigma-Aldrich
L-Ascorbic acid, ACS reagent, ≥99%
Sigma-Aldrich
L-Ascorbic acid, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
4-(Dimethylamino)benzaldehyde, puriss. p.a., reag. Ph. Eur., ≥99% (perchloric acid titration)
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
4-(Dimethylamino)benzaldehyde, 98%
Sigma-Aldrich
L-Ascorbic acid, tested according to Ph. Eur.
Supelco
4-Androstene-3,17-dione, VETRANAL®, analytical standard
Sigma-Aldrich
4-(Dimethylamino)benzoic acid, 98%
Sigma-Aldrich
L-Ascorbic acid, Vetec, reagent grade, 99%
Sigma-Aldrich
L-Ascorbic acid, FCC, FG
Valaciclovir impurity G, European Pharmacopoeia (EP) Reference Standard
Supelco
L-Ascorbic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Methanol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Methanol, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Methanol, HPLC Plus, ≥99.9%
Sigma-Aldrich
Methanol, suitable for HPLC, gradient grade, ≥99.9%